Besides breast cancer, uPAR amplification has also been frequently reported in pancreatic cancer and analogously recognized as a significant adverse prognostic parameter identifying a subgroup of particularly aggressive tumors [10]. This evidence concerns the gene PLAUR and familial pancreatic carcinoma.